Investors



Interim Summary

TurnoverQ4 2018

15 242

TSEK

EBITDAQ4 2018

-1 474

TSEK

Christer Ahlberg
President and CEO

CEO comments

The fourth and final quarter for 2018 is completed. A very eventful quarter and sales-wise successful. In the full year, we increased sales by 43% compared to 2017, which exceeds our ambition to increase on average 20% annually until the registration of IsoConDa in Europe.

In 2017, much of the internal work focused on making the company administratively clear for a listing. In 2018, the focus has been on the registration work of IsoConDa in Europe, AnaConDa and IsoConDa in the US and to prepare for a launch of IsoConDa in Europe. It has manifested itself in a number of ways. To begin with, I am pleased that the organization started to become clear. In 2018 we have built a medical and clinical department in order to have the competence within the company to manage the European registration work, but also lead the work with registrations in other countries. The work with shaping the organization will of course continue in the future but began seriously in 2018.

In parallel with our marketing manager starting in the last quarter, we have continued to develop our sales organization in several countries during the year. We have expanded our sales capacity in France and Spain, but above all in Germany, where we have now employed several people who will be able to realize Sedana Medical’s vision. We have also started up sales operations in other countries on a smaller scale. I would like to mention Norway, Denmark and the UK, where we during the year opened our own direct sales.

The fact that AnaConDa was approved in Japan in November is proof that Sedana Medical as a company has a good registration competence for medical technology products, which constitutes a solid basis for the future pharmaceutical registration process. The work of launching AnaConDa in Japan has begun through our distributor. Thanks to our targeted new share issue in the second quarter of 2018, we have also been able to initiate the work of getting our therapy approved in the US. The work of preparing the FDA meeting in March has been intensively carried out during the quarter. Our regulatory strategy is basically to get both our medical device product and our drug approved simultaneously. Regarding the registration work for IsoConDa (isoflurane) in Europe, most things go according to plan. It is gratifying that after the end of the quarter, we received approval for our planned pediatric study from the Pediatric Committee of EMA (PDCO), which ensures 10 years of exclusivity in the EU. The only setback that affected us during the year is the pause in the clinical registration study, which is now proceeding according to plan.

An important milestone on the road to becoming a pharmaceutical company is the health economic analysis that was published during the quarter. It shows the clinical and economic benefits of inhalation sedation of isoflurane via AnaConDa compared to conventional intravenous sedation with propofol or midazolam. To become commercially viable and successful, the therapy must also be accepted as a cost-effective alternative. In this process, the health economic study is a good start and a proof of the cost-effectiveness of therapy. Health economic documentation is needed to ensure that our proposed price level is approved in the markets we intend to launch. The health economic study also shows that we have taken the step seriously into the pharmaceutical field.

In summary, during the fourth quarter, and throughout 2018, we have taken a number of important development steps and built internal expertise in the company. We have run parallel tracks of registration work, clinical studies and health economic documentation. While we are working hard to get the therapy approved, we have built a sales and marketing organization with strategic expertise for global launch.

One of the most important steps in the registration of our therapy is the IsoConDa study, our pivotal phase III study aimed at getting the drug candidate IsoConDa (isoflurane) approved for inhalation sedation in intensive care in Europe. At the beginning of 2019, we received the interim analysis for the study, which pleasingly showed smaller variations in efficacy than anticipated and therefore the study will only need to cover a total of 300 patients instead of initially estimated 550 patients. This is very positive, and we now expect to submit an application for a market approval in the summer of 2020 in 16 European countries. If everything goes well, we can have a European market approval in the second half of 2021. The interim analysis is a milestone and we can now continue to work on the study at a rapid pace.

The fourth quarter and 2018 have been eventful, but in many ways, it is only the start of our journey. I look forward with excitement to the future.

Christer Ahlberg, President and CEO

 Read the report in its entirety here.

Calendar
Dates for upcoming information

Date Event
25 Apr 2019 Annual Report 2018
8 May 2019 Interim Report Q1 2019
14 May 2019 Redeye Medtech & Diagnostics Seminar – click here for more information.
28 May 2019 Annual General Meeting 2019
10 June 2019 Redeye Growth Day 2019 – click here for more information.
22 Aug 2019 Interim Report Q2 2019
13 Nov 2019 Interim Report Q3 2019
Content

Annual General Meeting 2018

Notice of Annual General Meeting in Sedana Medical AB (publ)
The shareholders in Sedana Medical AB (publ) are hereby summoned to attend the Annual General Meeting on Tuesday 22 May 2018 at 4 p.m. at. Erik Penser Bank, Apelbergsgatan 27, Stockholm. Registrations starts 15:30 CET.

Participation
Shareholders who wish to attend the Annual General Meeting must be listed as shareholders in the register kept by Euroclear Sweden AB on Wednesday, May 16, 2018, and must notify the company of their intention to participate in the meeting no later than Wednesday, May 16, 2018 at the following address: Sedana Medical AB (publ), Berga Backe 2, 182 53 Danderyd, Sweden. The registration can also be done by telephone +46 (0) 8- 124 05 200 or by e-mail to corp@sedanamedical.com. In the registration, name, address, telephone number (daytime), person / organization number, shareholding and information about possible representatives / assistants must be stated. There are a total of 17,280,538 shares and votes in Sedana Medical AB (publ). Shareholders represented by proxy shall issue a written, day-to-day power of attorney for the proxy or, should the right to vote for the shares be divided among different representatives, the representatives, together with information on the number of shares each representative is entitled to vote for. If the power of attorney is issued by a legal entity, a certified copy of the registration certificate or equivalent of the legal entity evidencing the authority to issue the proxy, shall be appended. The original power of attorney and any registration certificate should be sent to the company well before the meeting at the above address. Proxy form is available on the company’s website, www.sedanamedical.com. Shareholders who have registered in a nominee register by bank or securities depository must, in order to be entitled to participate in the meeting, register the shares in their own name. Such registration, which may be temporary, must be duly effected in the share register maintained by Euroclear Sweden AB on Wednesday, May 16, 2017, which means that the shareholders must notify the nominees well in advance of this date. Shareholders are reminded of their right to request information under Chapter 7. Section 32 of the Swedish Companies Act.

Proposed agenda
1. Opening of the meeting
2. Election of Chairman of the Meeting
3. Preparation and approval of the voting list
4. Election of two persons to approve the minutes of the meeting
5. Determination of whether the meeting has been duly convened
6. Approval of the agenda
7. Presentation of the annual report and the auditor’s report, the consolidated accounts and the consolidated audit report
8. Statement by the CEO, Christer Ahlberg
9. Resolution on approval of the statement of income and balance sheet and consolidated income statement and
consolidated balance sheet.
10. Resolution on allocation of the company’s earnings according to the established balance sheet
11. Resolution on discharge from liability of the members of the Board of Directors and the Managing Director
12. Determination of fees to the Board of Directors and the Auditor
13. Determination of the number of Board members and, where applicable, deputy members, as well as the number of auditors and any deputy auditors
14. Election of Board of Directors and Auditor and any deputy members
15. Resolution on principles for appointment and instruction regarding nomination committee
16. Resolution regarding authorization for the Board of Directors to issue new shares
17. Closing of the Meeting

Proposition for resolutions
Resolution on allocation of the company’s result (item 10)
The board of directors proposes that the company’s results shall be carried forward.

Board etc. (item 2 and 12–14)
Nomination Committee, consisting of:

  • Karl Tobieson, Chairman of the Nomination Committee and representing Linc AB
  • Sten Gibeck, owner and board member of Sedana Medical AB (publ)
  • Ola Magnusson, owner and board member of Sedana Medical AB (publ)
  • Tony McCarthy, representing Michael Ryan
  • Proposes the following:
  • Thomas Eklund to be elected chairman of the meeting (item 2).
  • The Board of Directors shall consist of six (6) members and no deputies. The Company shall have one Auditor and no deputy auditors. (item 13).
  • A total fee to the Board of Directors of SEK 525,000, of which SEK 225,000 to the Chairman of the Board, SEK 50,000 each to Sten Gibeck, Bengt Julander, Ola Magnusson and Michael Ryan, and SEK 100,000 to Eva Walde. (item 12).
  • Fees to the auditor in accordance with the approved invoice. (item 12).
  • Re-election of the board members Thomas Eklund, Sten Gibeck, Bengt Julander, Ola Magnusson och Michael Ryan and election of Eva Walde as new member of the board (item 14). Further information regarding the proposed board members to be found at www.sedanamedical.com.
  • Re-election of Thomas Eklund as Chairman of the Board (item 14).
  • Re-election of R3 as an audit company with mandate until the 2019 Annual General Meeting (item 14).

Principles for the appointment of the Nomination Committee and instructions for the Nomination Committee (item 15)
It is proposed that the AGM decides to establish principles for the appointment of the Nomination Committee in accordance with the following.

Principles of determination
The chairman of the board shall, by the end of the third quarter of Sedana Medical’s financial year each year, ensure that the company’s voting three largest shareholders or ownership groups are invited to each appoint each member to be included in the nomination committee. The reconciliation is based on Euroclear Sweden AB’s shareholder list (owner group) as of the last banking day in September or any other evidence that shareholders or group of owners at this time report as evidence of their shareholding. Where one or more shareholders refrain from appointing a member of the Nomination Committee, one or more of the following shareholders in ownership shall be offered to appoint a member of the Nomination Committee. However, no more than five additional shareholders need not to be contacted, unless the Chairman of the Board finds that there are special reasons for this. When shareholders are contacted with a request for the appearance of a member of the Nomination Committee, the Chairman of the Board shall make the necessary rules of procedure such as the latest response date, etc.

The Nomination Committee shall consist of a total of at least three members, including the Chairman of the Board, which is included in the Nomination Committee and convenes the first meeting of the Nomination Committee.

The composition of the Nomination Committee shall be published as soon as it has been appointed. The chairman of the nomination committee shall, unless the members agree otherwise, be the member appointed by the largest shareholder. However, the Chairman of the Board or other Board member shall not be the Chairman of the Nomination Committee. The Nomination Committee shall hold its mandate until a new Nomination Committee has been appointed. Fees shall not be paid to members of the Nomination Committee. The member shall leave the nomination committee if the shareholder who appointed this member no longer has substantially the same ownership interest as when the member was appointed. If the Nomination Committee subsequently ceases to have at least three members, the Chairman of the Board shall act for a new member to be appointed according to the principles stated above. However, if there are no special reasons, no changes shall be made to the composition of the Nomination Committee if only minor changes in the voting number have taken place or the change occurs later than two months before the AGM.

Shareholders who appoint a member of the Nomination Committee are entitled to vacate such a member and appoint a new member of the Nomination Committee.

Nomination Committee assignment
The Nomination Committee shall prepare and propose to the Annual General Meeting:

  • election of chairman of the meeting
  • election of the chairman or members of the board of directors in the company’s board of directors
  • election of auditor and, if applicable, auditor’s deputy
  • proposals for remuneration to the chairman, board members, auditor and, where appropriate, committee work
  • principles for the election of the nomination committee

The Chairman of the Board shall appropriately inform the Nomination Committee of information about the Board’s competence profile and working methods.

Meetings
The Nomination Committee shall meet when required to fulfill its duties, at least twice a year. Notice of attendance is issued by the Chairman of the Nomination Committee (except for the first meeting convened by the Chairman of the Board). The member may request that the Nomination Committee be convened.

The nomination committee is to decide if at least half of the members participate. However, decisions in cases may not be taken, as far as possible, all members could participate in the matter. The decision of the Nomination Committee applies to the opinion for which more than half of the members present vote, or, in the same number of votes, the meaning of the nomination committee’s chairman.

An account of the Nomination Committee’s work in the form of proposals and opinions from the Nomination Committee shall be published on the Company’s website in good time before the Annual General Meeting.

Changes to these instructions
The Nomination Committee shall regularly evaluate these instructions and the nomination committee’s work and submit to the Annual General Meeting proposals for such changes to this instruction deemed appropriate by the Nomination Committee.

Authorization for the board to resolve on new issue of shares (item 16)
The Board of Directors proposes that the Annual General Meeting authorizes the Board to resolve on a number of occasions prior to the next Annual General Meeting, with or without prejudice to shareholders’ preferential rights, a new issue of shares which, in aggregate, does not exceed 15 percent of the total number of outstanding shares after use of the authorization. A new issue may be issued with or without notice regarding the amount, offsetting or other conditions referred to in Chapter 13, Section 5, first paragraph, 6 of the Swedish Companies Act. The purpose of the authorization is to give the board flexibility in the work to ensure that the company can be appropriately allocated capital for the financing of the business, business or product acquisition, and to enable the company’s ownership base to be broadened.

*****

The annual report and other supporting documentation for resolutions will be available at the company’s offices, Sedana Medical AB (publ), Berga Backe 2, 182 53 Danderyd, and on www.sedanamedical.com, no later than three weeks prior to the meeting and will be sent to shareholders who so request and provide their postal address. All of the above documents will also be presented at the meeting. This notice is a translation of a Swedish notice and in case of any deviations between the both language versions, the Swedish version shall prevail.

Stockholm, April 2018, Sedana Medical AB (publ)
The Board of Directors

Downloadable files:

  Notice of Annual General Meeting
  Nomination Committee’s proposal
  Power of Attorney form
  Minutes of the Annual General Meeting


Corporate Governance

Corporate governance includes information about our Board of Directors, the management team, guidelines for remuneration to the senior management, our auditors, general meetings and our articles of association.

Board of Directors

The registered office of the company is situated in the municipality of Danderyd. The Board of Directors shall consist of not less than three (3) and not more than six (6) members, with not more than three (3) deputy members. Currently the Board of Directors consists of six (6) members elected at the Annual General Meeting on 22 May 2018 for the period until the end of the next Annual General Meeting.

Thomas Eklund Chairman
of the Board
  • Born: 1967
  • Position: Board member and Chairman of Sedana Medical since 2014.
  • Education and professional experience: Thomas holds an MBA from the Stockholm School of Economics. 25 years of experience from leading positions in banking, life science and healthcare. CEO, Investor Growth Capital (renamed as Patricia Industries) during 2002–2012, a private equity company owned by Investor AB with a focus on long-term investments in technology, industrial and healthcare. Former board member in life science companies, e.g. Swedish Orphan International AB (chairman) and Carmel Pharma AB.
  • Other current engagements: Chairman in Biotage AB, Caliditas Theraputics AB, Itrim Holding AB and Moberg Pharma AB (publ). Board member in Boule Diagnostics AB, Excillum Aktiebolag, Impilo No 4 Holding II AB, Memira Holding AB, Neoventa Medical AB, Rodebjer Form AB, SciBase Holding AB (publ), Surgical Science Sweden AB, Swedencare AB (publ) and board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 474,156 shares via Eklund Konsulting AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Sten GibeckMember
of the Board
  • Born: 1943
  • Position: Member of the Board of Sedana Medical since 2005. Formerly Chairman of the Board.
  • Education and professional experience: Sten holds a higher business economics qualification from the National Swedish Union of Clerical Employees. Sten is a former owner and CEO of Louis Gibeck AB during its journey from being a small distribution company to achieving a leading position in its field in e.g. Germany, France, Japan and the USA.
  • Other current engagements:
  • Shareholding in Sedana Medical: 1,605,744 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.
Bengt Julander Member
of the Board
  • Born: 1953
  • Position: Member of the Board of Sedana Medical since 2011.
  • Education and professional experience: Bengt is a qualified pharmacist, M.Sc. from Uppsala University. Bengt has more than 30 years of experience in the life science industry. Owner and Board member of Linc AB, with investments in the pharmaceutical and medtech industry.
  • Other current engagements: Chairman in Knil AB. Board member in Calliditas Therapeutics AB, Cronhamn Invest AB, Linc AB, Livland Skog AB Medivir Aktie¬bolag, Nefecon AB, nWise AB, ProEquo AB, Stille AB, Swevet AB and Swevet Holding AB. Deputy Board member in Eriksbergskliniken AB and board member and deputy board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 1,901,901 shares via Linc AB.
    Independent in relation to the Company and its management but not in relation to major shareholders.
Ola Magnusson
Member
of the Board
  • Born: 1948
  • Position: Member of the Board of Sedana Medical since 2005. Formerly CEO of Sedana Medical (2005 – 2011).
  • Education and professional experience: Ola holds an upper secondary school qualification in engineering specializing in chemistry from Gothenburg Technical Upper Secondary School. Ola has more than 25 years of experience in the pharmaceutical industry in Pharmacia and Kabi and 20 years of experience in the medical device industry in Louis Gibeck AB (CEO) and Hudson RCI as managing director EMEA.
  • Other current engagements: Chairman in Eataway AB and Transcutan AB. Board member in Hammarplast Medical Aktiebolag, Miris Holding AB (publ) and board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 1,296,000 shares via Magiola Consulting AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Michael Ryan Member
of the Board
  • Born: 1957
  • Position: Member of the Board of Sedana Medical since 2005. Former CEO of Sedana Medical (2011 – 2017).
  • Education and professional experience: Michael holds a Master of Industrial Engineering (1st Class Honours) from University College Dublin. Prior to becoming CEO of Sedana in 2011 Michael was the major shareholder and CEO of Artema Medical AB until it was acquired in 2008. He was also joint owner of Excal AB and has held leading positions in technology companies in Ireland and Sweden for over 25 years.
  • Other current engagements: CEO and Board member in TecScan Ireland Ltd. Board member in Anades Ltd, Irrus Investment Ltd, Salmur Ltd and Venn Life Sciences Ltd.
  • Shareholding in Sedana Medical: 1,068,083 shares via Anades Ltd. and 35 warrants representing 140,000 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.
Eva Walde Member
of the Board
  • Born: 1963
  • Position: Member of the Board of Sedana Medical since 2018.
  • Education and professional experience: Eva has a BSc from the School of Economics in Gothenburg, Sweden. Over 20 years of experience in the pharmaceutical and medical technology industry, mainly in marketing and sales as well as management. Formerly VP Commercial Operations, International Region at Phadia / ThermoFisher Scientific as well Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB.
  • Other current engagements: Currently working as a self-employed management consultant, CEO and Chairman of the board in Movits Consulting AB and also deputy board member in Finnson & Partners AB.
  • Shareholding in Sedana Medical: 3, 200 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.

Management team

Christer Ahlberg
President and CEO
  • Born: 1971
  • Position: President and Chief Executive Officer of Sedana Medical since February 2017.
  • Education and professional experience: Christer holds a BSc in business administration and economics from Örebro University.Former experience in the pharmaceutical industry includes CEO at Unimedic Group (2010–2016), CEO at Eisai AB (2005–2010) and more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth.
  • Other current engagements: Board member in Anthrop Pharmaceuticals AB and Sedana Medical Ltd.
    CEO and board member in Sedana Medical Sarl. CEO and deputy board member in Waxholm by the sea aktiebolag. Deputy board member in Sedana Medical Incentive AB.
  • Shareholding in Sedana Medical: 230,000 shares and 184,200 warrants representing 184,200 shares.
Maria Engström
CFO
  • Born: 1972
  • Position: Chief Financial Officer of Sedana Medical since February 2017.
  • Education and professional experience: Maria holds a BSc in business administration and economics from Stockholm University. Former managing director at Cross Pharma AB (2015–2016) and Head of Business Control at Medivir AB (2012–2014). More than 15 years of experience in positions as finance manager, head of business control and controller at Biovitrum, Bristol Myers Squibb and Ericsson.
  • Other current engagements: Board Member in FAYSIT – Finance At Your Service In Tyresö AB.
    Deputy board member in UHT Förvaltning AB.
  • Shareholding in Sedana Medical: 3,850 shares and 60,782 warrants representing 60,782 shares via FAYSIT – Finance At Your Service In Tyresö AB.
Peter Sackey
CMO
  • Born: 1971
  • Position: Chief Medical Officer of Sedana Medical since January 2018.
  • Education and professional experience: Peter received his doctor´s degree from Karolinska Institutet in 1997. He has worked for twenty years at the Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital and is Board-certified in Anesthesiology (DESA) and Intensive Care (EDIC). He completed his PhD thesis entitled “Isoflurane sedation in Intensive Care Unit patients” at Karolinska Institutet in 2006. He is an Associate professor at Karolinska Institutet, has supervised several PhD students and has active ICU-related research.
  • Previous positions: Senior Consultant, Head of Neurocritical Care, Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital in Stockholm.
  • Other current engagements: Associate professor, Department of Physiology and Pharmacology, Karolinska Institutet.
  • Shareholding in Sedana Medical: 975 shares and 65,167 warrants representing 65,167 shares.
Ron Farrell
Vice President Head of R&D and Quality
  • Born: 1956
  • Position: Vice President Head of R&D and Quality at Sedana Medical since 2011. COO of Sedana Medical Ltd.
  • Education and professional experience: Ron has a graduateship in Plastics and Rubber from the Institute of London (GPRI). More than 37 years of experience in the manufacturing industry at e.g. Oral-B Laboratories, Gillette, Vistakon, Tech Group, Artema Medical and Kayfoam Woolfson. Main areas of competence include engineering, quality assurance, supply chain, development and operation management.
  • Other current engagements: Board member in Lismed Ltd. and Sedana Medical Ltd.
  • Shareholding in Sedana Medical: 731,062 shares and 55 warrants representing 220,000 shares.
Robert vom Dorp
Vice President Head of Sales
  • Born: 1970
  • Position: Vice President Head of Sales at Sedana Medical since 2010, employee since 2005.
  • Education and professional experience: Robert holds an MBA in economics from the University of Applied Sciences at Hochschule Koblenz. Has also studied industrial organisation. Experience in sales in the medtech industry since 2001 as account manager within anaesthesia, ventilation and intensive care at Hudson RCI and Teleflex Medical. Sales manager at Sedana Medical with responsibilities for marketing, sales, strategy and operations in Germany, Austria and Switzerland.
  • Other current engagements:
  • Shareholding in Sedana Medical: 7,500 shares and 26 warrants representing 104,000 shares.
Gunilla Mickelsson
Vice President Head of Marketing
  • Born: 1971
  • Position: Vice President Head of Marketing of Sedana Medical since October 2018.
  • Education and professional experience: Gunilla holds a degree of BSc in Business Administration and Economics from Örebro University. Previous positions as Head of Global Marketing in the Specialty Care Unit at Swedish Orphan Biovitrum, and before that Senior Director of Commercial Strategies and Alliance Management at Sobi Partner Products.
  • Previous positions: More than 20 years of experience in various commercial and leadership roles in pharmaceutical companies like AstraZeneca, Meda, Wyeth and Pfizer.
  • Other current engagements: Board member in Kapfovaltre AB.
  • Shareholding in Sedana Medical: 1500 shares.

Guidelines for remuneration to senior management

The main principle is that remuneration and other employment conditions for members of senior manage¬ment shall be based on market terms and be competitive in order to ensure that the group can attract and retain competent senior managers at a reasonable cost for the company.

The total remuneration for senior management shall consist of fixed salary, variable remuneration, pension and other benefits.

The Board fee is decided by the Annual General Meeting. In so far as board members elected by the Annual General Meeting are performing work that stretches beyond the tasks of the Board of Directors, it shall be possible to pay them for such work. Such remuneration shall be market-based and shall be approved by the Board of Directors.

At the Annual General Meeting on 19 May 2017 it was resolved that the fees payable to the Board of Directors for the period until the end of the Annual General Meeting 2018 shall amount to a total of SEK 350,000, of which SEK 150,000 shall be paid to the Chairman of the Board of Directors and SEK 50,000 to each of the other ordinary board members.

Auditor

Christina Kallin Sharpe, authorised public accountant at R3 Revisionsbyrå was re-elected as auditor for the company until the end of the next Annual General Meeting.

General Meeting

The General Meeting of shareholders is the highest decision-making entity in Sedana Medical AB. At the General Meeting, all shareholders are invited to exercise their rights according to their respective shareholdings.

Shareholders wishing to participate in General Meetings must be listed as a shareholder in a printout or other presentation of the entire share register reflecting the circumstances five weekdays before the General Meeting and notify the company no later than the date specified in the notice of the General Meeting. A shareholder may be accompanied by advisers at a General Meeting only if he or she notifies the company of the number of advisers in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

Articles of Association

§ 1 Name of the company
The name of the company is Sedana Medical AB (publ).

§ 2 Registered office of the Board of Directors
The registered office of the company shall be situated in the municipality of Danderyd.

§ 3 Object of the company’s activities
The object of the company’s activities is to develop, manufacture and market pharmaceuticals and medical-technical products, and other activities compatible therewith.

§ 4 Share capital
The share capital shall be not less than SEK 800,000 and not more than SEK 3,200,000.

§ 5 Number of shares
The number of shares shall be not less than 8,000,000 and not more than 32,000,000.

§ 6 Board of Directors
The Board of Directors shall consist of not less than three (3) and not more than six (6) members with not more than three (3) deputy members. The members are to be elected annually at the Annual General Meeting until the end of the next Annual General Meeting.

§ 7 Auditors
The company shall have a minimum of one (1) and a maximum of two (2) auditors, with a maximum of two (2) deputy auditors.

§ 8 Place of General Meetings
Any General Meeting of the company shall be held in Danderyd or Stockholm.

§ 9 Notice of General Meeting
Notices of General Meetings shall be made by announcement in the Swedish Official Gazette (Sw. Post- och Inrikes Tidningar) and by making the notice available on the company’s website. At the same time as notice is given it shall be announced in Dagens industri that a notice has been made.
Shareholders wishing to participate in General Meetings must be listed as shareholder in a printout or other presentation of the entire share register reflecting the circumstances five weekdays before the General Meeting and notify the company no later than the date specified in the notice of the General Meeting. The last mentioned date may not be a Sunday, other public holiday, Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday before the general meeting. A shareholder may be accompanied by advisers at a General Meeting only if he or she notifies the company of the number of advisers in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

§ 10 Annual General Meeting
The following matters shall be addressed at the Annual General Meeting:

1. Election of Chairman of the meeting

2. Preparation and approval of the voting register

3. Election of one or two persons to attest the minutes

4. Determination of whether the meeting has been duly convened

5. Approval of the agenda

6. Presentation of the annual report and auditor’s report and, where applicable, the consolidated financial statements and the auditor’s report on the group

7. Resolutions regarding:

(a) adoption of the balance sheet and income statement and, where applicable, the consolidated balance sheet and the consolidated income statement

(b) disposition av bolagets vinst eller förlust enligt den fastställda balansräkningen

(c) discharge from liability for the Board of Directors and the managing director

8. Determination of fees to be paid to the Board of Directors and the auditors

9. Determination of the number of board members and, where applicable, deputy members, and the number of auditors and, where applicable, deputy auditors

10. Election of the Board of Directors and auditors

11. Any other business incumbent on the meeting according to the Swedish Companies Act or the articles of association

§ 11 Financial year
The company’s financial year shall be 1 January – 31 December.

§ 12 CSD clause
The shares of the company shall be registered in a CSD register in accordance with the Central Securities Depositaries and Financial Instruments Accounts Act (Sw. lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument).

Ownership

Below is Sedana Medical’s ownership structure as of December 31, 2018.

Name Number of shares Shareholding (%)
Linc AB 1 901 901 9,93%
Sten Gibeck 1 605 744 8,38%
Magiola Consulting 1 355 867 7,08%
Anders Walldov direkt och indirekt (Brohuvudet AB) 1 160 000 6,06%
Anades Ltd. 1 068 083 5,58%
State Street Bank & Trust 796 123 4,16%
Ron Farrell 731 062 3,82%
SEB 723 216 3,78%
Handelsbanken Microcap 592 990 3,10%
Eklund Konsulting AB 474 156 2,48%
BNP Paribas 457 085 2,39%
Swedbank Robur Microcap 450 000 2,35%
Avanza pension 448 709 2,34%
Nordnet Pensionsförsäkring AB 404 090 2,11%
Pershing, LLC 368 877 1,93%
Fifteen largest shareholders 12 537 903 65,45%
Others * 6 618 688 34,55%
TOTAL: 19 156 591 100%

* Of which CEO’s ownership is 230 000 shares.

Warrant programmes

Sedana Medical has two outstanding warrant programmes with a total maximum dilution of 1 350 149 shares.

Warrant 2014/2019, total maximum dilution of 1 040 000 shares, exercisable until 31 December 2019
at a strike price of 2,50 SEK/share.

Warrant 2017/2021, total maximum dilution of 310 149 shares, exercisable until 31 January 2021
at a strike price equaling 130% of the IPO price.

Presentations

Date Description Material
May 8, 2019 Presentation of the interim report for the first quarter 2019.  Play Video
March 14, 2019 Stockholm Corporate Finance Life Science Seminar.  Play Video
March 12, 2019 Presentation of the year-end report 2018.  Play Video
March 8, 2019 IsoConDa phase III pivotal study, interim analysis report, 8 March 10:30.  Play Video
November 22, 2018 Presentation of the interim report for the third quarter 2018.  Play Video  View PDF
September 6, 2018 Pareto Securities’ 9th Health Care seminar in Stockholm.  Play Video
August 30, 2018 Presentation of the interim report for the second quarter 2018.  Play Video
May 22, 2018 Presentation of the interim report for the first quarter 2018.  Play Video
April 27, 2018 Event at ProHearings (English).  Play Video
March 7, 2018 Sitdown at Erik Penser 2018 (Swedish).  Play Video
March 6, 2018 Stockholm Corporate Finance Life Science Seminar (Swedish).  Play Video
November 24, 2017 Redeye seminar (Swedish).  Play Video
June 29, 2017 Trading Direkt Interview with CEO Christer Ahlberg (Swedish).  Play Video

Shares

Share
ISIN-code
Share
Shortname
Current
Share Price
SE0009947534 SEDANA  Click here!
Certified Adviser: Erik Penser Bank – Tel: +46 (0)8-463 80 00 – Apelbergsgatan 27, Box 7405, 103 91 Stockholm, Sweden
Analyst(s) covering Sedana Medical: Peter Östling, Pareto Securities

IPO

 Sedana Medical Investor Relation

 

Address:
Sedana Medical AB (publ)
Vendevägen 87
SE-182 32 Danderyd
Sweden
Phone: +46 (0)8-124 05 200
Investor relation: ir@sedanamedical.com


Abonnieren Sie Unseren Newsletter

Nach der Registrierung erhalten Sie aktuelle Neuigkeiten direkt in Ihr Postfach.
Klicken Hier für den Newsletter anmelden